Search

• ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis

  Media

  INSPIRING study results contribute to extensive body of evidence for dolutegravir

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/

  First published: 05 March 2018

• ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

  Media

  SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca for treatment of virologically suppressed adults with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/

  First published: 03 April 2019

• ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

  Media

  Recommendation based on GEMINI 1 & 2 studies which demonstrated non-inferior efficacy.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-dovato-dolutegravirlamivudine-as-a-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-infection/

  First published: 26 April 2019

• ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

  Media

  ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/

  First published: 02 July 2020

• Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

  Media

  Licences should enable potentially millions of people living in areas most impacted by HIV to access innovative prevention medicine.

  https://www.gsk.com/en-gb/media/press-releases/medicines-patent-pool-signs-sublicences-with-aurobindo-cipla-and-viatris-to-produce-generic-versions-of-viiv-healthcare-s-innovative-long-acting-hiv-prevention-medicine/

  First published: 30 March 2023

• ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

  Media

  ViiV - GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir & lamivudine continues to demonstrate high efficacy rates

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-gemini-1-2-studies-through-week-96-showing-2-drug-regimen-of-dolutegravir-plus-lamivudine-continues-to-demonstrate-high-efficacy-rates/

  First published: 24 July 2019

• ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

  Media

  The approval is based on the pivotal phase III ATLAS and FLAIR studies that included more than 1,100 patients from 16 countries.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/

  First published: 21 January 2021

• ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

  Media

  ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/

  First published: 18 November 2016

• ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

  Media

  Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravirlamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection/

  First published: 03 July 2019

• New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression

  Media

  ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study

  https://www.gsk.com/en-gb/media/press-releases/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/

  First published: 23 September 2015